secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neumora Therapeutics, Inc. (NMRA)
CIK:        0001885522
Form:       8-K
Filed at:   2026-08-14T11:13:22+00:00
Accession:  0001193125-26-350349
Event type: leadership
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neumora appoints Joshua Pinto as CEO, narrows Q2 net loss to $43.1M
-------------------------------------------------------------------

- Joshua Pinto named CEO and Board member; Paul Berns becomes Executive Chair, effective Aug 14, 2026.
- Doron Sagman, M.D., appointed Chief Medical Officer; brings 20+ years of clinical development experience.
- Q2 2026 net loss $43.1M vs $52.7M in Q2 2025; R&D $29.3M, G&A $12.9M; cash $116.8M as of June 30, 2026.
- Pipeline: NMRA-215 IND Q4 2026, Phase 1 by end 2026; NMRA-511 MAD data Q4 2026 and Phase 2 initiation by end 2026; NMRA-898 Phase 1 data H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1885522/000119312526350349/0001193125-26-350349-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1885522/000119312526350349/nmra-20260814.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-350349

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer